Abstract: A system and method produce a treated effluent from untreated wastewater. An untreated wastewater is obtained from a wastewater source and processed in a membrane bioreactor to produce treated effluent. The treated effluent is then processed in the first reverse osmosis system. Optionally, an effluent permeate produced by the first reverse osmosis system is injected into a subterranean formation through an injection well, wherein formation water is subsequently extracted from the subterranean formation through a recovery well and processed in a reverse osmosis system to produce a permeate water stream which may be supplied to a potable water distribution system.

Abstract: A magnetic flowmeter for sensing process fluid flow includes a flow tube configured to receive the process fluid flow there through and a plurality of electrodes disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. A flow tube liner is provided in the flow tube having an interior surface configured to contact process fluid and an exterior surface mounted to the flow tube. The flow tube liner has at least one adhesion feature in the exterior surface which promotes adhesion between the flow tube liner and the flow tube. A method is also provided.

Abstract: A magnetic flowmeter for sensing process fluid flow includes a flow tube configured to receive the process fluid flow there through and a plurality of electrodes disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. A flow tube liner is provided in the flow tube having an interior surface configured to contact process fluid and an exterior surface mounted to the flow tube. The flow tube liner has at least one adhesion feature in the exterior surface which promotes adhesion between the flow tube liner and the flow tube. A method is also provided.

Abstract: A composite flow tube liner includes a cylindrical substrate and an interior layer. The cylindrical substrate includes a plurality of perforations and is configured for installation within a flow tube assembly of a magnetic flowmeter. The interior layer includes a fluoroelastomer and covers an interior surface of the substrate. The interior layer extends into the perforations of the cylindrical substrate, which secures the fluoroelastomer to the cylindrical substrate.

Abstract: A composite flow tube liner includes a cylindrical substrate and an interior layer. The cylindrical substrate includes a plurality of perforations and is configured for installation within a flow tube assembly of a magnetic flowmeter. The interior layer includes a fluoroelastomer and covers an interior surface of the substrate. The interior layer extends into the perforations of the cylindrical substrate, which secures the fluoroelastomer to the cylindrical substrate.

Abstract: A flowtube assembly for a magnetic flowmeter is provided. The flowtube assembly includes a flowtube configured to receive a flow of process fluid therethrough. A magnetic core is mounted relative to the flowtube and includes a stem extending from the flowtube to a pair of arms. Each of the arms extends away from the stem. A spool having a plurality of magnetic windings is disposed about the stem and spaces the plurality of windings from the flowtube.

Abstract: A magnetic flowmeter for sensing process fluid flow is provided. The flowmeter includes a tube configured to receive the process fluid flow therethrough. A plurality of electrodes is disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. Flowmeter electronics are configured to drive a current through at least one electromagnetic coil and to sense a signal developed across a plurality of electrodes disposed to contact process fluid. A flexible circuit module is disposed proximate the tube, and has at least one flexible circuit containing a plurality of electrical traces electrically coupled to the flowmeter electronics. The at least one electromagnetic coil includes a first coil in the flexible circuit module that is coupled to the electrical traces.

Abstract: A flowtube assembly for a magnetic flowmeter is provided. The flowtube assembly includes a flowtube configured to receive a flow of process fluid therethrough. A magnetic core is mounted relative to the flowtube and includes a stem extending from the flowtube to a pair of arms. Each of the arms extends away from the stem. A spool having a plurality of magnetic windings is disposed about the stem and spaces the plurality of windings from the flowtube.

Abstract: A magnetic flowmeter for sensing process fluid flow is provided. The flowmeter includes a tube configured to receive the process fluid flow therethrough. A plurality of electrodes is disposed to contact process fluid. At least one electromagnetic coil is disposed proximate the tube. Flowmeter electronics are configured to drive a current through at least one electromagnetic coil and to sense a signal developed across a plurality of electrodes disposed to contact process fluid. A flexible circuit module is disposed proximate the tube, and has at least one flexible circuit containing a plurality of electrical traces electrically coupled to the flowmeter electronics. The at least one electromagnetic coil includes a first coil in the flexible circuit module that is coupled to the electrical traces.

Abstract: This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain pentafluorosulpholane-containing compounds of the formula or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain bridged and fused compounds of the formula G-L-A I or a pharmaceutically acceptable salt, ester of solvate thereof wherein: A is: (I) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: This invention provides for certain bridged and fused heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, ester solvate or prodrug thereof wherein: L is: (II) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders.

Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Abstract: Compounds of formula (I) 1

Abstract: Compounds of formula (I) 1

Abstract: The invention relates to serine protease inhibitor compounds of formula (I) where R1 is hydrogen, halo, cyano, nitro or hydroxyl, amino, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, thiol, alkylthio, aminosulphonyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl, cycloalkyl, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, haloalkoxy and haloalkyl; R2 is hydrogen, halo, methyl, amino, hydroxy, or oxo; and R is X—X—Y(R7)—L—Lp(D)n; wherein each X independently is a C, N, O or S atom or a CO, CR1, C(R1)2 or NR1 group, at least one X being C, CO, CR1 or a C(R1)2 group; Y (the &agr;-atom) is a nitrogen atom or a CR1 group or Y and L taken together form a cyclic group; R7 is a lipophilic group selected from alkyl, alkenyl, mono- or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylalkenyl, aralkyl, heteroaryl-alkyl